Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: NASDAQ.COM
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PACB with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PACB
Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.40 USD with a low forecast of 2.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.380
Low
2.00
Averages
2.40
High
3.00
Current: 2.380
Low
2.00
Averages
2.40
High
3.00
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
Continue Reading
Pacific Biosciences (PACB) Reports 14% Q4 Revenue Growth for 2025
- Revenue Growth: Pacific Biosciences anticipates approximately $44.6 million in Q4 2025 revenue, up 14% from $39.2 million in the prior year, driven by strong sales of its Vega sequencing platform, indicating robust performance.
- Instrument and Consumables Revenue: Q4 2025 instrument revenue is expected to rise to $17.3 million from $15.3 million, while consumables revenue jumps from $18.8 million to $21.6 million, reflecting sustained market demand and operational efficiency.
- System Deployment Trends: The placement count for the Vega system surged to 42 units in Q4 2025 from 7 units year-over-year, while the Revio system placements declined from 23 to 21 units, highlighting a shift in market preference towards Vega amid challenges for Revio.
- Future Outlook: CEO Christian Henry noted that the SPRQ-Nx technology's cost reductions and enhanced multiomic capabilities are expected to catalyze growth in 2026 and beyond, demonstrating the company's confidence in future market opportunities.
Continue Reading